# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Upgrades
Credit Suisse analyst Evan Seigerman maintains Aimmune Therapeutics (NASDAQ:AIMT) with a Neutral and raises the price targe...
Goldman Sachs raised the price target for Zoom Video Communications Inc (NASDAQ: ZM) from $187 to $402. Zoom Video shares r...
Cantor Fitzgerald downgrades Aimmune Therapeutics (NASDAQ:AIMT) from Overweight to Neutral and raises the price target from $...
Wedbush analyst Liana Moussatos downgrades Aimmune Therapeutics (NASDAQ:AIMT) from Outperform to Neutral and lowers the pric...
Gainers Aimmune Therapeutics, Inc (NASDAQ: AIMT) shares jumped 171.6% to close at $34.22 on Monday after Nestle SA agreed to...
-Reuters
Toward the end of trading Monday, the Dow traded down 0.72% to 28446.24 while the NASDAQ rose 1% to 11,812.92. The S&P also...
Gainers Aimmune Therapeutics, Inc (NASDAQ: AIMT) shares climbed 171.5% to $34.21 after Nestle SA agreed to acquire the compa...